Adaptimmune Ther ADR (ADAP)

Mar 20, 2025, 12:10 PM EDT - 5 weeks ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 5 weeks ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 12, 2025, 4:54 PM EDT - 6 weeks ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Jan 30, 2025, 4:00 PM EST - 3 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 13, 2025, 8:00 AM EST - 3 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Dec 19, 2024, 7:30 AM EST - 4 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 2, 2024, 4:00 PM EST - 5 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Nov 13, 2024, 7:48 PM EST - 5 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 5 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 9:00 AM EST - 5 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 5, 2024, 9:19 AM EST - 6 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Oct 31, 2024, 5:20 PM EDT - 6 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 8 months ago

Adaptimmune to Participate in Two Bank Conferences this September

Aug 12, 2024, 11:42 AM EDT - 9 months ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:00 AM EDT - 9 months ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 5, 2024, 8:00 AM EDT - 9 months ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 2, 2024, 9:20 AM EDT - 9 months ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 1, 2024, 8:20 PM EDT - 9 months ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Jul 3, 2024, 9:54 AM EDT - 10 months ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jun 17, 2024, 2:05 PM EDT - 11 months ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 3, 2024, 12:00 PM EDT - 11 months ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

May 30, 2024, 4:01 PM EDT - 11 months ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

May 30, 2024, 4:01 PM EDT - 11 months ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Dec 6, 2023, 7:00 AM EST - 1 year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 8, 2023, 11:45 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:30 AM EST - 1 year ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:05 AM EST - 1 year ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 25, 2023, 8:06 AM EDT - 1 year ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Oct 23, 2023, 4:15 AM EDT - 1 year ago

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Sep 12, 2023, 8:48 AM EDT - 1 year ago

Adaptimmune: Spinning Sarcoma Into Gold

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

Aug 9, 2023, 10:18 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 7:29 AM EDT - 1 year ago

Adaptimmune Reports Second Quarter Financial Results and Business Update

Aug 3, 2023, 1:24 PM EDT - 1 year ago

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023